gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CELUHealthcarePharmaceuticals

Celularity Inc. Class A Common Stock (CELU)

$0.8088−1.02%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$0.81▼ 52.98% in range
Nov 4, 2025Low $0.60 · High $2.10Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Celularity closed at $0.81 on Nov 4, down 1.02%, 61.5% below its 52-week closing high. Volume of 72.1K shares was 0.45× its 20-day average (below normal).

Split-adjusted performance: -48.8% over one month, -13.0% over six months, -53.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $5.43M, down 5.3% from a year earlier, with a net margin of 10.1%.

Short interest was 441.8K shares at the Oct 15 settlement, up 12.9% from the prior report (6.7% of float, 3.7 days to cover).

Market cap$26.2M32.4M shares
Revenue · quarter$5.4M−5.3% YoY
Diluted EPS$0.02—
P/E · TTM—P/S 1.4×
Net margin10.1%Gross 56.8%
Dividend yieldNone
52-week range0.60 – 2.10−61.5% from high
Volume72.1K0.45× 20-day avg
Volatility · 60d223.1%Annualised
Short % of float6.7%3.7 days to cover
Net cash-$37.1MCash $586.0K
Next earnings—Not scheduled
Split-adjusted performance
1W −14.0%1M −48.8%3M +18.4%6M −13.0%YTD −27.1%1Y −53.0%3Y −61.5%5Y −98.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum62
Revenue growth37
Net margin79
Value (low P/E)—
Size24

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short441.8K+12.9% vs prior
Days to cover3.7Settled Oct 15
% of float6.7%
Short vol. 10d56.7%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CELUCelularity$0.8088−1.02%−13.0%−5.3%10.1%—$26.2M
ABVCABVC BioPharma$1.00+1.51%−9.1%———$26.7MCompare
NXTCNextCure$5.85−1.02%−45.4%———$26.8MCompare
RNAZTransCode Therapeutics$1.60+1.91%−78.7%———$27.1MCompare
CPHIChina Pharma Holdings$0.5875−3.56%+11.4%−7.5%−153.8%—$25.3MCompare
AARDAardvark Therapeutics$1.26+2.44%−78.6%———$27.6MCompare
FLNAFilana Therapeutics$0.5720−3.75%————$27.6MCompare
SHPHShuttle Pharmaceuticals Holdings$5.21+1.17%−33.2%———$24.8MCompare
BCTXBriacell Therapeutics$3.19+5.98%−23.1%———$27.9MCompare

News about Celularity

All news →
Celularity Provides Update Regarding Nasdaq Listing ComplianceGlobeNewswire Inc. · Aug 25, 2026▼ NegativeCelularity Receives Nasdaq Notice Regarding Form 10-QGlobeNewswire Inc. · May 29, 2026▼ NegativeEXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple RevenueBenzinga · Mar 10, 2026Neutral

Quick answers

What does Celularity do?
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
What is CELU's market cap?
$26.25M, based on the Nov 4 close of $0.81.
Does Celularity pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CELU is sold short?
441.8K shares, 6.7% of float, as of Oct 15, 2026.
What sector is CELU in?
Healthcare, in the Pharmaceuticals industry.

About Celularity

Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.

HQ: Florham Park, NJ115 employeesListed Jul 19, 2021celularity.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology